STOPAMI 1 & 2 Predictive Factors and Impact of No-Reflow After Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction.

Slides:



Advertisements
Similar presentations
ISAR-TEST-2 Trial Two-year Clinical and Angiographic Outcomes from a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents versus Polymer-Based Cypher.
Advertisements

August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
Prospective, Randomized Trial of Paclitaxel- versus Sirolimus- Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents Robert A.
© 2010, American Heart Association. All rights Association of Hospital Primary Angioplasty Volume in ST-Segment Elevation Myocardial Infarction With Quality.
UNIVERSITÄT LEIPZIG H E R Z Z E N T R U M Randomized Comparison of Percutaneous Coronary Intervention with Sirolimus-Eluting Stents versus Coronary Artery.
The value of DES in unprotected left main lesions has not been evaluated by dedicated randomized clinical trials. Especially, it is not known whether currently.
The EMERALD Trial Diabetic Substudy. EMERALD Diabetic Analysis To compare myocardial perfusion and infarct sizes in diabetic and non-diabetic patients.
Protection Devices in PCI-Treatment of Myocardial Infarction for Salvage of Endangered Myocardium Study Presented at American College of Cardiology Scientific.
Facilitated PCI & rescue PCI Dolly mathew. Primary PCI is the preferred reperfusion strategy in STEMI Most patients donot arrive at the PCI center within.
J. Mehilli, A. Kastrati, K. Huber, S. Schulz, J. Pache, C.Markwardt, S. Kufner, F. Dotzer, K. Schlotterbeck, J. Dirschinger, A. Schömig Abciximab in Patients.
J. Mehilli, A. Kastrati, K. Huber, S. Schulz, J. Pache, C.Markwardt, S. Kufner, F. Dotzer, K. Schlotterbeck, J. Dirschinger, A. Schömig. Abciximab in Patients.
ISAR-TEST-2 Trial Two-year Clinical and Angiographic Outcomes from a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents versus Polymer-Based Cypher.
Utilization of Rescue and Facilitated Angioplasty for Primary PCI: Who Should Get Lytic Therapy in 2009? Adnan Kastrati Deutsches Herzzentrum, Technische.
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
J. Mehilli, MD, G. Richard, F-J. Neumann, S. Massberg, K-L. Laugwitz, J. Pache, J. Hausleiter, I. Ott, M. Fusaro, T. Ibrahim, A. Schömig, A. Kastrati Deutsches.
Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial O.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
ISAR-TEST 5: Randomized, Non-inferiority Trial of Rapamycin/Probucol- and Zotarolimus-Eluting Stents J. Mehilli, MD A. Kastrati, R.A. Byrne, S. Massberg,
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 53 Management of ST-Elevation Myocardial Infarction.
The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing.
Murat Sezer, Emre Aslanger, Arif Cimen, Ebru Yormaz, Cuneyt Turkmen, Berrin Umman, Yılmaz Nisanci, Zehra Bugra and Sabahattin Umman Istanbul University,
Effect of Intracoronary Streptokinase Administered Immediately after Primary PCI on Left Ventricular Infarct Size, Volume and Function (J Am Coll Cardiol.
Angiographic Estimates of Myocardium at Risk During Acute Myocardial Infarction: a Validation Study Using Cardiac MRI José T. Ortiz, Sheridan N. Meyers,
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
UNIVERSITÄT LEIPZIG H E R Z Z E N T R U M Infarct transmurality and infarct size assessed by delayed enhancement magnetic resonance imaging: Association.
Neointimal Modification with Scoring-Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients with Restenosis in Drug- Eluting Coronary Stents Deutsches.
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli M.D., Francesco.
Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic.
Randomized Early versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial) Mauro Maioli, MD, Francesco.
Impaired RV Global Longitudinal Strain Is Associated With Poor Long-Term Clinical Outcomes in Patients With Acute Inferior STEMI Journal of the American.
Randomized, non-inferiority trial of three limus agent- eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results:
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.
M-Guard stent in STEMI patients with high thrombus burden lesions Mahmoud Shabestari Baktash Bayani Ali Eshraghi Bahram Shahri Mashhad University.
Total Occlusion Study of Canada (TOSCA-2) Trial
The American College of Cardiology Presented by Dr. Adnan Kastrati
Management of ST-Elevation Myocardial Infarction
ISAR-TEST-2 Trial Two-year Clinical and Angiographic Outcomes from a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents versus Polymer-Based Cypher.
Presenter Disclosure Information
Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) - press conference - Katrin.
Circ Cardiovasc Interv
Presented by Dr. Leif Thuesen
European Society of Cardiology 2003
Giuseppe Biondi Zoccai, MD
Figure 1 PCI strategies in patients with STEMI and multivessel disease
Nat. Rev. Cardiol. doi: /nrcardio
Published in the European Heart Journal
American Heart Association Presented by Dr. Julinda Mehilli
American College of Cardiology Presented by Dr. Michel R. Le May
National Trends in the Incidence, Management, and Outcomes of Heart Failure Complications in Patients Hospitalized for ST-Segment Elevation Myocardial.
Impact of Diabetes Mellitus on Long-term Outcomes in the
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Infarct Size after Primary Angioplasty Patients With Bivalirudin
A New Angiographic Risk Score in Facilitated PCI
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
Evolution of Myocardial Blush after MI
A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Presentation transcript:

STOPAMI 1 & 2 Predictive Factors and Impact of No-Reflow After Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Gjin Ndrepepa, Klaus Tiroch, Dritan Keta, Massimiliano Fusaro, Melchior Seyfarth, Jürgen Pache, Julinda Mehilli, Albert Schömig, Adnan Kastrati Deutsches Herzzentrum München, Technische Universität, Munich, Germany 1

STOPAMI 1 & 2 Objectives of the Study The Relationship Between No-reflow and Myocardial Salvage Quantified by Scintigraphic Studies Before and after Primary PCI Predictive Factors of No-reflow after Primary PCI The Persistence or Resolution of No-reflow in the 6-month Angiography The Impact of No-reflow on the Left Ventricular Function at 6 Months and One-year Mortality 2

STOPAMI 1 & 2 Methods Baseline Tc-sestamibi Scintigraphy Primary Percutaneous Coronary Intervention (PCI) Tc-sestamibi Scintigraphy 7-14 Days After PCI 6-Month Coronary Angiography One-year Follow-up 1140 Patients with Acute ST-Segment Elevation Myocardial Infarction (STEMI) 3

STOPAMI 1 & 2 Diagnosis of No-reflow and Outcomes Diagnosis: 1.Angiographic Evidence of Re-opening of Occluded Coronary Artery with no Evidence of Flow-limiting Residual Stenosis. 2.Angiographic Documentation of TIMI Flow Grade ≤ 2, at Least 10 Minutes after the End of PCI Procedure Outcomes: Primary Outcome: One-year Mortality Secondary Outcomes: - Amount of Myocardial Salvage - Predictive factors of No-reflow - Left Ventricular Ejection Fraction at 6 Months after Primary PCI 4

STOPAMI 1 & 2 Scintigraphic Parameters I nitial Area at Risk: Perfusion Defect in the Baseline Scintigraphy (% of the Left Ventricle) Infarct Size: Perfusion Defect in the 7-14 Days Scintigraphy (% of the Left Ventricle) Absolute Salvage: Initial Area at Risk Minus Infarct Size (% of the Left Ventricle) Salvage index: Initial Area at Risk Minus Infarct Size Divided by Initial Area at Risk (Proportion of Salvaged Initial Area at Risk). 5

STOPAMI 1 & 2 Differences in Baseline Characteristics 6

STOPAMI 1 & 2 Angiographic Data Type of intervention 0.96 Stenting 88 (81.5) 843 (81.7) Balloon angioplasty 20 (18.5) 189 (18.3) Pre-procedural abciximab therapy 84 (77.8) 800 (77.5) 0.95 Data are median [25th; 75th percentiles] or number of patients (%) 7

STOPAMI 1 & 2 Scintigraphic Data VariableNo-reflow (n =108) Reflow (n =1032) P value Initial Area at Risk (% of LV)26.0 [18.5; 52.5] 24.0 [14.0; 40.0] Infarct Size at 7-14 days (% of LV)18.9 [10.3; 33.8] 9.1 [3.0; 20.9] <0.001 Absolute Salvage (% of LV)9.8 [5.3; 16.3] 12.0 [5.0; 21.0] 0.04 Salvage Index0.34 [0.15; 0.49] 0.55 [0.29; 0.81] <0.001 Data Are Median [Interquartile Range] 8

STOPAMI 1 & 2 Salvage Index % of Left Ventricle P=0.008 No-reflow Reflow P<0.001 No-reflow Reflow Initial Area at Risk Final Infarct Size 9

STOPAMI 1 & 2 Salvage Index Reflow (TIMI Grade 3) No-reflow (TIMI Grade ≤2) Salvage index P<0.001 Ndrepepa et al. Circ Cardiovasc Interv. 2010;

STOPAMI 1 & 2 Predictors of No-reflow Variable Unadjusted Odds Ratio [95% Confidence Interval] Adjusted Odds Ratio [95% Confidence Interval] Previous myocardial infarction 1.71 [ ]2.17 [ ] C-reactive protein (for 1mg/L increase) 1.02 [ ]1.02 [ ] Baseline TIMI flow grade (for 1 grade decrease) 1.98 [ ]2.02 [ ] Initial area at Risk (for 5% of the LV increase) 1.10 [ ]1.07 [ ] 11

STOPAMI 1 & 2 No-reflow (TIMI 0-2) (n =76) Reflow (TIMI 3) (n = 867) TIMI Flow Grade in the 6-Month Angiography Suboptimal Flow (TIMI 0-2) (n =121) Normal Flow (TIMI 3) (n = 822) 761 (87.8%) 61 (80.3%) 106 (12.2%) 15 (19.7%) Post-primary PCI TIMI Flow Grade Ndrepepa et al. Circ Cardiovasc Interv. 2010; Time-course of TIMI Flow 12

STOPAMI 1 & 2 Left ventricular Ejection Fraction at 6 Months After PCI Reflow No-reflow  EF at 6 months P=  EF at 6 months Resolution of No-reflow Persistence of No-reflow P=0.002 % Ndrepepa et al. Circ Cardiovasc Interv. 2010;

STOPAMI 1 & 2 One-year Survival Months Numbers at Risk No-reflow Reflow Probability of survival (%) Hazard Ratio = 3.35, 95 CI ; P<0.001 Reflow (5.5%) No-reflow (16.7%) Ndrepepa et al. Circ Cardiovasc Interv. 2010;

STOPAMI 1 & 2 Predictors of One-Year Mortality 15

STOPAMI 1 & 2 Main Findings and Conclusions No-Reflow after Primary PCI is Associated with Considerable Reduction of the Myocardial Salvage, Worse Left Ventricular Function and Increased One-Year Mortality Independent Predictors of No-reflow were: - Absence of Residual Blood Flow in the Infarct-Related Artery - Large Infarct Size - Previous Myocardial Infarction - Elevated Level of C-reactive Protein Normalization of Blood Flow Occurs in 80% of Patients 6 Months After Primary PCI Resolution of Blood Flow is Associated with Significantly Better Left Ventricular Function Compared with Persistence of No-reflow 6 Months after Primary PCI 16